methylphenidate + selective serotonin reuptake inhibitor + serotonin-norepinephrine reuptake inhibitor

This is a **combination therapy** consisting of three drug classes: methylphenidate (a central nervous system stimulant and norepinephrine-dopamine reuptake inhibitor), a selective serotonin reuptake inhibitor (SSRI), and a serotonin-norepinephrine reuptake inhibitor (SNRI). This combination is employed clinically in situations where complex psychiatric comorbidity is present, such as attention-deficit/hyperactivity disorder (ADHD) with anxiety and/or depression. Methylphenidate increases synaptic dopamine and norepinephrine, while SSRIs and SNRIs increase serotonin (and norepinephrine, in the case of SNRIs). The combination may potentiate or modify the neural effects of each drug, particularly in the striatum, with increased risk of behavioral side effects and possibly addiction liability compared to monotherapy. The components are generally prescribed by psychiatrists for individualized treatment plans; there is no commercial product or fixed-dose combination comprising these three components[1][2][3].